A randomized, double-blind, parallel, single dose comparative pharmacokinetic study of two humanized monoclonal antibodies targeting HER2 receptors (i.e. trastuzumab) in healthy adult male subjects

Trial Profile

A randomized, double-blind, parallel, single dose comparative pharmacokinetic study of two humanized monoclonal antibodies targeting HER2 receptors (i.e. trastuzumab) in healthy adult male subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Nov 2016

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Pharmacokinetics
  • Acronyms TZ-01-003
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 17 Nov 2016 Status changed from not yet recruiting to completed.
    • 04 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top